

Message

From: BHAKTA, TINA [AG/1005] [tina.bhakta@bayer.com]
Sent: 6/6/2019 7:33:33 PM
To: Goodis, Michael [Goodis.Michael@epa.gov]; BHAKTA, TINA [AG/1005] [TINA.BHAKTA@BAYER.COM]; Keigwin, Richard [Keigwin.Richard@epa.gov]; Echeverria, Marietta [Echeverria.Marietta@epa.gov]
CC: MARVIN, THOMAS [AG/1920] [thomas.marvin@monsanto.com]
Subject: Re: Roundup Xtend 2 Complete Potential EUP Study Locations

Mike,

Good to hear from you. We look forward to hearing from you next week and we would be happy to answer any questions that you might have.

Thanks again

Tina

From: "Goodis, Michael" <Goodis.Michael@epa.gov>
Date: Thursday, June 6, 2019 at 1:28 PM
To: "BHAKTA, TINA [AG/1005]" <TINA.BHAKTA@BAYER.COM>, "Keigwin, Richard" <Keigwin.Richard@epa.gov>, "Echeverria, Marietta" <Echeverria.Marietta@epa.gov>
Cc: THOMAS MARVIN <thomas.marvin@monsanto.com>
Subject: RE: Roundup Xtend 2 Complete Potential EUP Study Locations

Hi Tina

Thanks for reaching out to us. We have been reviewing the submitted material and are discussing it among the team. I don't think we are ready yet to talk this week but are likely to have some questions around mid/late next week. We will be in contact to arrange a time when we get closer next week. Thanks

Michael L. Goodis, P.E.
Director, Registration Division (RD)
Office of Pesticide Programs (OPP)

Phone 703-308-8157
Room S7623

From: BHAKTA, TINA [AG/1005] <tina.bhakta@bayer.com>
Sent: Wednesday, June 05, 2019 10:03 AM
To: Keigwin, Richard <Keigwin.Richard@epa.gov>; Goodis, Michael <Goodis.Michael@epa.gov>; Echeverria, Marietta <Echeverria.Marietta@epa.gov>
Cc: MARVIN, THOMAS [AG/1920] <thomas.marvin@monsanto.com>
Subject: FW: Roundup Xtend 2 Complete Potential EUP Study Locations

Mike and Team,

I wanted to let you know that we shared two potential locations that could be repurposed for the work for our new dicamba formulation. The bottom line is that these two locations could accommodate the same study design that we have aligned with EFED on for the T&C for the Xtendimax registration in IL and MO bootheel. Because the locations are already planted there is a timing component which is reflected in the slides attached (end of June/early July target spray) for which an EUP approval would be needed.

Since the EUP scope is to conduct additional broader scope of work on product performance for 2020; would there be an opportunity to have the focus for review to be on the GLP drift vol work that that EFED would need to review as part of the section 3 registration? Just a thought for consideration?

Tom Orr has shared with Reuben and Dan this morning so we hope that we can discuss further if needed this week to assess if there is any potential for these locations to be sprayed with the new formulation in 2019. If there is any additional information that is needed please feel free to reach out or if you feel a call may be warranted as we would be happy to do that this week.

Thanks

Tina

From: THOMAS ORR <thomas.b.orr@monsanto.com>

Date: Wednesday, June 5, 2019 at 7:51 AM

To: "Baris, Reuben" <Baris.Reuben@epa.gov>

Cc: "Kenny, Daniel" <Kenny.Dan@epa.gov>, "BHAKTA, TINA [AG/1005]" <tina.bhakta@monsanto.com>, THOMAS MARVIN <thomas.marvin@monsanto.com>

Subject: Roundup Xtend 2 Complete Potential EUP Study Locations

Hi Reuben. As we discussed, Bayer has some fields that were planted for dicamba research this summer that could potentially be repurposed for EUP testing, pending EUP approval of course. Please see attached slide deck that provides some additional information for each of the two potential locations. Both locations could potentially accommodate the same study design that is currently being used for the XtendiMax Condition of Registration studies this season.

Tina and I would be happy to hop on a brief call later this week or early next week to discuss further if needed.

Best regards,

Tom Orr

Global Regulatory Affairs Manager

//////////

Bayer Crop Science
Monsanto Company
Regulatory Science
Building FF
Chesterfield, 63017, USA
Tel: +1 636-737-9347
Cell: +1 314-422-1748
E-mail: thomas.orr@bayer.com
Web: <http://www.bayer.com>

/// Follow Bayer on:

/// [Twitter](#) /// [Facebook](#) /// [Instagram](#) /// [LinkedIn](#) /// [YouTube](#)

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.